期刊文献+

迪之雅对糖尿病肾病治疗效果的临床研究 被引量:2

CLINICAL STUDY OF DIZHIYA IN TREATING DIABETIC NEPHROPATHY
下载PDF
导出
摘要 目的:探讨迪之雅对糖尿病肾病治疗效果。方法:将100例糖尿病肾病患者,分为糖尿病肾病组1和糖尿病肾病组2,再随机分为迪之雅组和对照组。结果:治疗16周,迪之雅组24h尿蛋白测定、尿β2微球蛋白水平均有明显下降,血清一氧化氮上升,血浆内皮素1水平明显下降。结论:提示迪之雅对糖尿病肾病的治疗能取得较好的效果,从远景上可延缓糖尿病肾病患者的肾功能损害。 Objective: Purpose To find the result of . Methods: Dizhiya treatment lor dicbetic nepnnopamy, One hundred type 2 diabetic patients with diabetic nephropathy were divided into first group and second group. And then they were all randomly divided into control group and Dizhiya ( Candesartan Cilexetil) treatment group. Results: Urinary albumin excretion rate , urinaryβ2 - microglobulin excretion, and plasma endothelin - 1 levels in Dizhiya ( Candesartan Cilexetil)treatment group were significantly decreased but serum nitric oxide has the contrary result after 16 weeks treatment. Conclusion:This finding suggests that the treatment of the Dizhiya ( Candesartan Cilexetil) can postpone the evolution of Diumserabetic nephropathies.
出处 《牡丹江医学院学报》 2007年第2期14-16,共3页 Journal of Mudanjiang Medical University
关键词 迪之雅 糖尿病肾病 血清一氧化氮 血浆内皮素 尿Β2微球蛋白 24h尿蛋白测定 Dizhiya ( Candesartan Cilexetil) diumserabetic nephropathies Nitric oxide endothelin urinaryβ2 -microglobulin excretion urinary albumin excretion rate
  • 相关文献

参考文献8

  • 1胡钢英,王晋明,李庚山.血管紧张素Ⅱ受体阻滞剂的临床研究现状[J].国外医学(内科学分册),2001,28(4):143-146. 被引量:23
  • 2刘智勇,袁兴红,杨永淑.不同期糖尿病肾病血浆一氧化氮、内皮素、氧化低密度脂蛋白水平变化[J].中华内分泌代谢杂志,2001,17(5):305-305. 被引量:13
  • 3Waeber B.A review of irbesartan in antihypertensive therapy:comparison with other antihytensive agents.Curr Ther Res Clin Exp,2001,62:505-523.
  • 4Lewis EJ,Hunsicker LG,Clarke WR,et al.Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type2diabetes.N Engl J Med,2001,345:851 -860.
  • 5Leppluoto J,Ruskoaho H.Endothelin pep tides biological activities,cellular signalling and clinical significance.Ann Med,1992,24:1532161.
  • 6Parving HH,Lehnert H,Brochner-Mortensen J,et al.The effect of irbesartan on the development of diabetic nephropathy in patients with type2diabetes.N Engl J Med,2001,345:870 -878.
  • 7Schmitz A,Vaeth M.Microalbuminuria:a major risk factor in non-insulin-dependent diabetes:A10-year follow-up study of503patients.Diabet Med,1998,5:126-134.1 Parving HH,Lehnert H,Brochner2Mortensen J,et al.The effect of Irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.N Engl J Med,2001,345:8702878.
  • 8Lewis EJ,HunsickerLG,ClarkeWR,et al.Renop rotective effect of the angiotensin2recep tor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.N Engl J Med,2001,345:8512860.

二级参考文献3

  • 1孙玲玲 徐成斌.今日高血压(第1版)[M].北京:中国医药科技出版社,2000.645-646.
  • 2Lgnarro LJ,Buga GM,Wood KS,et al.Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide[].Proceedings of the National Academy of Sciences of the United States of America.1997
  • 3Benigni A,Colsiol V,Brena C,et al.Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes[].Diabetes.1998

共引文献34

同被引文献15

引证文献2

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部